RT @BetaKit: .@amplitudeVC closes $263 million for second precision medicine VC fund. #healthtech #CDNtech

Thanks to @SeanSilcoff and @globeandmail for featuring us in their latest article.

We are pleased to announce the $263M final close of our second Precision Medicine fund to build companies at the intersection of AI/ML and Biology. Read more below.

We are expanding our team and are looking for an Investor to join us in Alberta! . Ideal candidates will have at minimum a Master's degree in science, experience in business, and exposure to AI and ML . See below for more information.

Big announcement today with Amplitude portfolio company, @radiantbio receiving a grant from The Bill and Melinda Gates Foundation to advance the Multabody™ platform against HIV. Congrats! .

We are excited about launching Reverb Therapeutics from stealth mode! . Reverb is building its Amplifier platform, a first-in-class approach that amplifies endogenous cytokines and directs them to tissues of interest. To learn more, see here -

We are excited to join forces with @Evotec to turbocharge precision medicine with the launch of our new venture studio, Pre-Amp!. This partnership integrates Amplitude's expertise in venture creation with Evotec's industrialized drug discovery platforms.

This morning, one of our portfolio companies, @valence_ai, was acquired by @RecursionPharma for $47M US. Congratulations to @_danielcohen, @Therence_mtl and the Valence team on building a world-leading AI computational chemistry platform company!.

Congratulations to the Evommune team on their funding round to bring new therapies to treat serious inflammatory diseases. We are pleased to work with the stellar team and add the company to the Amplitude portfolio. For more of our thoughts, see below:.

Our revolutionary antibody platform company, Radiant Biotherapeutics, leading the new frontier of multi-valent, multi-specific therapeutics emerging from stealth with an $8M seed round and multiple strategic partnerships.

Huge congratulations to @abdera_thera on their $142M US Series A + B Financing. Another example of world-class innovation advancing forward for patients. For our thoughts on the company, please see our blog post below - .

Happy International Women's Day from the Amplitude team!. Today we celebrate the amazing and diverse women at Amplitude and within our portfolio companies who continue to inspire and do great things every day.

We're now accepting applications for our 2023 Fellowship. Check out the information below and please pass it on to anyone who would be interested!.

Do you want to stay rooted in health and life science while exploring the dynamic and creative scientific impact you can have as an entrepreneur? The Amplitude Fellowship may be what you’re looking for. Learn more& apply HERE -->

NOW RECRUITING! The application deadline for the 2023 Fellowship Program is March 31st. Are you an outstanding life science focused PhD candidate, post doc, MD, or inventor?.

We're pleased to announce the addition of our new controller Riccardo!. Before joining Amplitude, Riccardo was the Shared Services Controller at @CellCarta, a global CRO. Welcome to the team Rick!.

This morning, @PrileniaTx announced that SV Health Investors has joined the Series B round as the company prepares for ALS and HD data readouts in the next 12 months. For more information, please see below.

Congratulations to the @DrugBankDB team on the recent fundraising and we look forward to working with you to help grow the company!. In collaboration with @BrightsparkVC we wrote a post on why we're excited about this opportunity, which you can find below.

@DrugBankDB's platform is helping scientists and entrepreneurs all over the world be able to build better, more precise drugs for patients and we see tremendous potential for their dataset to be used to design new approaches to drug discovery with AI and ML approaches.

This morning, @DrugBankDB announced the closing of a $9M oversubscribed seed round and we're excited to add this company to our portfolio.